VolitionRx Limited VNRX PHARMA

Healthcare · Medical Devices · United States

https://volition.com

Company Profile ↓

$0.33

-97.32% 1Y

Mkt Cap$9.21M

P/E-0.09

P/B-0.10

52W High$13.80

52W Low$0.33

Book Value$-2.67

EPS (TTM)$-3.85

Company Overview

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 68.2%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 63.6% CAGR over the past five years.

Recent Developments

Dec 2025 Revenue of $1.73M (+40.0% YoY); net profit $-23.36M.
Trailing 12 Months Year-on-year growth — revenue -2.0%.
5-Year Trend Long-term compounding — revenue CAGR 63.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	63.64%
1 Year:	-2.00%

Stock Price Performance

1 Year:	-97.32%
6 Months:	-91.69%
3 Months:	-76.09%
1 Month:	-57.40%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 0% of range

$0.33 $13.80

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)27.26 · Oversold

Price Performance

1M-57.40%

3M-76.09%

6M-91.69%

1Y-97.32%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 68.2%.
Compounding revenue at 63.6% over 5 years.

CONS

Trading 97.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.09

Industry PE

24.83

Forward P/E

-0.39

PEG Ratio

Book Value

$-2.67

Price to Book

-0.10

P/S

2.95

EV/EBITDA

-0.58

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

63.64%

Profit 5Y

Revenue (YoY)

-2.00%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

68.20%

ROA

Profit Margin

0.00%

Op Margin

Gross Margin

100.00%

EPS (Latest Qtr)

$-0.97

EPS (TTM)

$-3.85

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.23

Current Ratio

0.30

Debt

$11.41M

Total Assets

$9.04M

Current Assets

$4.52M

Working Capital

$-10.17M

Ownership

Promoter Holding

3.58%

Chg in Prom Hold

-3.74%

FII / Inst Holding

11.63%

Chg in FII Hold

-11.98%

Financial Snapshot

Enterprise Value

$9.21M

Total Revenue (TTM)

$2.46M

EBITDA

$-18.57M

Free Cash Flow

$-9.21M

Operating Cash Flow

$-19.56M

Shares Outstanding

27.90M

Gross Margin

100.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	VNRX VolitionRx Limited PHARMA	0.33	-0.09	$9.21M	0.00%	-	68.20%	63.64%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	14.79K	-	-	-	-	-	-	-	-	-	-	-	-	-	0	17.10K	544	5.19K	575	25.53K	24.78K	25.48K	114.21K	39.75K	32.71K	149.81K	216.31K	165.21K	171.53K	395.80K	474.52K	-	246.38K	406.69K	627.28K	447.03K	985.08K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.65M	6.63M	5.50M	5.18M	6.21M
Operating Income	-925.57K	-1.24M	-1.05M	-1.76M	-2.35M	-2.02M	-2.97M	-2.49M	-2.98M	-3.48M	-3.34M	-3.44M	-3.88M	-4.63M	-4.57M	-4.45M	-3.99M	-4.15M	-4.18M	-5.87M	-5.21M	-4.50M	-6.09M	-5.90M	-7.56M	-7.68M	-8.10M	-7.99M	-9.05M	-9.55M	-8.65M	-8.38M	-6.99M	-5.87M	-	-5.40M	-6.22M	-4.87M	-4.73M	-5.23M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.07M	-5.55M	-4.23M	-4.95M	-5.87M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96.67K	448.66K	873.43K	1.07M	575.98K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.48M	-6.31M	-5.41M	-6.30M	-6.70M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-925.57K	-2.19M	816.80K	-5.89M	-2.01M	-1.87M	-2.96M	-2.49M	-2.95M	-3.48M	-3.35M	-3.46M	-3.89M	-4.65M	-4.59M	-4.48M	-4.20M	-4.16M	-4.18M	-5.86M	-5.04M	-4.34M	-6.13M	-5.57M	-7.18M	-7.72M	-7.73M	-7.81M	-8.87M	-9.55M	-8.45M	-8.37M	-6.99M	-5.82M	-	-5.42M	-6.28M	-5.38M	-6.27M	-6.66M
Diluted EPS	-	-	0.06	-0.44	-	-0.10	-0.16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.10	-0.08	-0.07	-	-1.12	-1.20	-1.00	-	-0.97
R&D Expense	524.53K	870.46K	791.29K	1.07M	1.21M	1.36M	1.86M	1.46M	1.75M	1.97M	1.67M	1.81M	2.13M	2.42M	2.69M	2.74M	2.47M	2.48M	2.64M	3.89M	3.49M	3.18M	3.87M	2.94M	3.61M	3.59M	3.28M	4.00M	4.91M	5.45M	4.65M	4.63M	3.72M	3.47M	-	2.61M	2.72M	2.29M	-	2.85M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	54.97K	-	14.79K	-	-	-	-	17.10K	13.43K	-	306.39K	775.30K	1.23M	1.73M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	30.86M	36.55M	28.16M	22.95M
Operating Income	-2.61M	-4.08M	-4.58M	-5.95M	-10.01M	-12.43M	-14.70M	-17.90M	-16.04M	-21.25M	-	-30.55M	-35.77M	-26.92M	-21.22M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-29.24M	-34.04M	-25.58M	-19.80M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	173.09K	221.62K	340.36K	2.49M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-30.60M	-35.68M	-27.26M	-23.50M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-2.61M	-4.08M	-3.71M	-8.21M	-9.53M	-11.91M	-14.77M	-18.01M	-16.10M	-20.40M	-	-30.27M	-35.32M	-26.97M	-23.36M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-11.00	-10.00	-6.20	-4.40
R&D Expense	1.52M	2.77M	2.50M	4.04M	6.10M	7.90M	8.03M	10.91M	10.36M	14.53M	13.02M	15.33M	19.55M	14.41M	10.08M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	2.25M	2.22M	2.07M	3.43M	7.71M	24.73M	14.62M	17.49M	21.29M	26.15M	27.49M	18.30M	27.95M	9.40M	6.90M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	12.17M	21.85M	4.06M	2.06M
Cash & Equivalents	47.48K	347.89K	376.42K	-	2.14M	5.92M	21.68M	10.12M	13.43M	16.97M	19.44M	20.58M	10.87M	20.73M	3.26M	1.12M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	72.61K	242.62K	110.57K	317.81K
Total Liabilities	-	1.16M	1.38M	1.39M	3.06M	1.67M	3.56M	4.67M	5.35M	7.09M	9.86M	9.77M	21.42M	36.66M	35.51M	42.49M
Current Liabilities	-	534.36K	747.77K	957.27K	2.71M	1.12M	2.03M	2.29M	2.33M	3.86M	6.24M	6.52M	17.39M	8.94M	7.79M	12.23M
Long Term Debt	-	-	-	-	-	20.37K	432.03K	1.31M	1.98M	2.20M	2.61M	2.27M	2.78M	3.62M	3.95M	7.26M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	4.97M	5.86M	5.82M	11.46M
Total Equity	-	1.09M	833.79K	680.67K	368.18K	6.04M	21.18M	9.96M	12.14M	14.20M	16.29M	17.72M	-2.57M	-7.80M	-24.91M	-34.25M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	2.89M	4.09M	4.80M	6.29M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.65M	-2.31M	-3.08M	-4.14M	-8.55M	-8.86M	-12.19M	-14.73M	-12.74M	-16.46M	-	-15.28M	-18.06M	-25.89M	-19.68M
Investing Cash Flow	-34.87K	-90.69K	-714	-302.99K	-132.19K	-415.09K	-1.43M	-301.81K	-511.27K	-1.65M	-	-1.57M	-1.08M	-573.85K	-89.56K
Financing Cash Flow	1.98M	2.47M	3.59M	5.74M	12.44M	25.19M	1.97M	17.97M	16.93M	20.62M	-	6.94M	28.98M	8.66M	17.09M
Capital Expenditure	-34.87K	-90.69K	-714	-302.99K	-77.19K	-415.09K	-1.43M	301.81K	-511.27K	-1.94M	-	-1.57M	-1.08M	-573.85K	-89.56K
Free Cash Flow	-1.69M	-2.41M	-3.08M	-4.44M	-8.62M	-9.28M	-13.62M	-14.43M	-13.25M	-18.41M	-	-16.85M	-19.15M	-26.47M	-19.77M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-9.91M	9.84M	-17.81M	-2.68M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	0	31.77K	0	-

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-7,428.0%	-	-40,258.4%	-	-	-	-	-93,840.2%	-158,176.2%	-	-9,971.1%	-4,614.1%	-2,182.5%	-1,228.6%
Net Margin %	-	-7,428.0%	-	-55,553.1%	-	-	-	-	-94,168.5%	-151,859.6%	-	-9,879.1%	-4,555.5%	-2,186.3%	-1,352.2%
ROE %	-239.5%	-489.7%	-545.1%	-2,230.9%	-157.7%	-56.2%	-148.3%	-148.3%	-113.4%	-125.2%	-	1,175.5%	452.7%	108.3%	68.2%
ROCE %	-152.5%	-277.9%	-411.0%	-826.7%	-151.8%	-54.8%	-119.2%	-118.1%	-92.0%	-106.7%	-	-3,361.0%	-188.2%	-1,673.4%	398.2%

Shareholding Pattern

Insiders

3.58%

Institutions

11.63%

Public Float

12.06%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Lagoda Investment Management, L.P.	7.77%	1.46M	$378.55K
2	Luminus Management, LLC	0.84%	156.90K	$40.79K
3	Geode Capital Management, LLC	0.30%	55.54K	$14.44K
4	Vanguard Capital Management LLC	0.27%	50.68K	$13.18K
5	Wealthspire Advisors, LLC	0.24%	45.00K	$11.70K
6	State Street Corporation	0.18%	33.99K	$8.84K
7	Xtx Topco Ltd	0.14%	25.38K	$6.60K
8	Vanguard Fiduciary Trust Co	0.13%	25.13K	$6.53K
9	Blackrock Inc.	0.12%	22.31K	$5.80K
10	Northern Trust Corporation	0.07%	12.98K	$3.37K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VNRX

Google News ue, 08 Sep 2026

VolitionRx (NYSE: VNRX) details Lind note and warrant stake under 4.99% cap - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdlo3SXdxdlVYQU9ZQUNJSVEwVXpWN3p6T3I0ejlTZklkSWpsblQ2QmRBcHFvSGQzMG9VZ2VkdFhvWWVSeklPOHplTHBNN21xQlBIUWdIb2JQN0ZIT1RzenBUNDd0YnNycWZBTTVGalZpOE91MmVSUXBrV1lKX29Za1FydkRXZXh1enNIM2…

Google News Sat, 11 Jul 2026

VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNT20xS3pvaGdmSzBJR1FwRDNGRGdnMkV2Wkc3ZVBiYVBmZHRMcUQxMUR4MUdtRUZjR0M1dXd0QWVqdXl3RHVoRWRxbUdkRFAxbWVkbE14bHlVZ29QdG5URERzT0hmclo2RGhKVVFhUUxmTjNpaG0yMV9ydXlMSUpxeE5lWkxNeHU4R3dxdG…

Google News hu, 25 Jun 2026

VNRX Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFB3eXB3VHFfLU1vRWYxV0hqelNCUXUtTDlhdzJ6dUxaVGxvLTRCd3Y4ckVYUVhhLWRYTnJEaENRRmZxOG5zUTFBTGotSHhDOEc5ZlRjYk5RTVJpNFpDeUZPWHprSmc5RW9EcFFtLW9XcFc5dmViYjln?oc=5" target="_blank">VNRX Fo…

Google News Wed, 18 Mar 2026

Why Is VNRX Stock Soaring Over 30% Today? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQZUltMldWSU5UVUxUMC05YlQxckwwM0MwZUxTQ282OEYtcFByZFZFNU4yM1AtakdnUWQyOEZUTXpWSXlFS3ZVOVp2dEhpVWp0V2lZVGRuSmVDRDUzV2ZLNllJQ05JcWtFQkZQeWdxVEVGYVlkZU54NUNxbkpab1pnaERsS2NLUThKLV9vM2…

Google News Fri, 04 Sep 2026

$11M VolitionRx (VNRX) stake comes with call to cut executive pay - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOem5kb3dma3lwUVEyQUJDMElCSGNZQkJ3cVBwVGV2QTVHQWZ0a2tpQ2FNVk5xNU1HenVGb1FFQnA2Uld4MUJPSTR2VFY1TEtrdWlyOUhibFRSRk5peFkyTUxVWmN5WV9WWDBxeXp2OTllUV9ySS1vUUNpZGcwa2htUDctY3pLcWNnLVRubW…

Google News Wed, 27 May 2026

VNRX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBkclRpVk5HeU16RmlxM3haVlhpOWFTbDNKcnJzVTBmeV9FM0FId2VMY0tEYmN5UXlabG5hdXAyRWtKYk1tdmc?oc=5" target="_blank">VNRX</a>  <font color="#6f6f6f">Finviz</font>…

VNRX — Frequently Asked Questions

What is the current share price of VolitionRx Limited (VNRX)?

As of 2026-09-19 21:16 PDT, VolitionRx Limited (VNRX) trades at $0.33 on NYSE American. Its 52-week range is $0.33 to $13.80.

What is the market capitalisation of VNRX?

VolitionRx Limited (VNRX) has a market capitalisation of $9.21M on NYSE American.

What is the P/E ratio of VNRX?

VNRX trades at a trailing price-to-earnings (P/E) ratio of -0.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.10.

What is the return on equity (ROE) of VNRX?

VNRX has a return on equity (ROE) of 68.20%.

Is VNRX a good stock to buy?

This page provides a data-driven analysis of VolitionRx Limited (VNRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

VolitionRx Limited VNRX PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

VolitionRx (NYSE: VNRX) details Lind note and warrant stake under 4.99% cap - Stock Titan

VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution - finance.yahoo.com

VNRX Forecast — Price Target — Prediction for 2027 - tradingview.com

Why Is VNRX Stock Soaring Over 30% Today? - Stocktwits

$11M VolitionRx (VNRX) stake comes with call to cut executive pay - Stock Titan

VNRX - Finviz

VNRX — Frequently Asked Questions

What is the current share price of VolitionRx Limited (VNRX)?

What is the market capitalisation of VNRX?

What is the P/E ratio of VNRX?

What is the return on equity (ROE) of VNRX?

Is VNRX a good stock to buy?

Explore More